Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: an open-label pilot study.
about
Use of Atypical Antipsychotics in the Treatment of Autistic DisorderAntipsychotics in the treatment of autismRisperidone for autism spectrum disorderEfficacy and tolerability of pharmacotherapy options for the treatment of irritability in autistic childrenOff-label indications for atypical antipsychotics: A systematic reviewAggression in autism spectrum disorder: presentation and treatment optionsThe status of pharmacotherapy for autism spectrum disordersPharmacotherapy to control behavioral symptoms in children with autismLong-term treatment with clozapine in an adult with autistic disorder accompanied by aggressive behaviourTranslational Mouse Models of Autism: Advancing Toward Pharmacological Therapeutics.Pharmacological management in children and adolescents with pervasive developmental disorder.Aripiprazole in pervasive developmental disorder not otherwise specified and Asperger's disorder: a 14-week, prospective, open-label study.A systematic review of the use of atypical antipsychotics in autism.Synergistic action of 5-HT2A antagonists and selective serotonin reuptake inhibitors in neuropsychiatric disorders.Paediatric uses of atypical antipsychotics.Pharmacotherapeutic management of autism.Use of olanzapine in non-psychotic psychiatric disorders.Developing drugs for core social and communication impairment in autism.Treatment of the special patient with schizophrenia.Systematic review of randomized controlled trials of atypical antipsychotics and selective serotonin reuptake inhibitors for behavioural problems associated with pervasive developmental disorders.Metabolic side effects of atypical antipsychotics in children: a literature review.Pharmacologic treatments for the behavioral symptoms associated with autism spectrum disorders across the lifespan.Role of risperidone in children with autism spectrum disorder.Review of antipsychotics in children and adolescents.Control of psychomotor agitation and aggressive behavior in patients with autistic disorder: a retrospective chart review.Recent advances in the pharmacotherapy of autism.Atypical antipsychotics in the treatment of children and adolescents with pervasive developmental disorders.Autism spectrum disorders: an overview on diagnosis and treatment.What's in the pipeline? Drugs in development for autism spectrum disorder.Antipsychotics use in children and adolescents: An on-going challenge in clinical practice.Multidisciplinary assessment and treatment of self-injurious behavior in autism spectrum disorder and intellectual disability: integration of psychological and biological theory and approach.Asperger's syndrome: diagnosis, comorbidity and therapy.Atypical antipsychotics in the treatment of pathological aggression in children and adolescents: literature review and clinical recommendations.Outcome measures in intervention trials for adults with autism spectrum disorders; a systematic review of assessments of core autism features and associated emotional and behavioural problems.Efficacy of antipsychotics for irritability and aggression in children: a meta-analysis.Psychopharmacological interventions in autism spectrum disorder.Olanzapine in the treatment of pervasive developmental disorders: a case series analysisSide-effects of risperidone therapy mimicking cerebrospinal fluid shunt malfunction: implications for clinical monitoring and management.Olanzapine in diverse syndromal and subsyndromal exacerbations of bipolar disorders.Atypical antipsychotic medication poisoning: an evidence-based consensus guideline for out-of-hospital management.
P2860
Q22241555-B8475665-B2B1-4933-BACF-6B260B1AFC66Q22241891-85E1C55E-5D72-4240-B9AC-EA98D8A3D2A0Q24246471-36AECFB3-4836-45C5-974F-96CD32F2BFB1Q24564288-DCD5FA8F-E41F-49A9-9917-B54B4140708CQ24803302-829F7CA8-81A5-487F-B12E-27E36C4F322BQ26744346-65C89400-DE28-409E-9E4C-B4BD00EB2AAAQ28239931-0B156D77-9851-48C0-A914-5EEB830C503EQ28265801-2388070F-CB24-47B3-BB8D-3671037D3B1DQ28361182-881E89E2-6C49-4B77-9263-91751D82586FQ28394524-D0639145-E008-4608-84E9-606FAC7DE0B3Q33521748-EC33062A-2E77-49F6-90E6-D221DA08AF5FQ33858314-56321506-A7C6-4629-A27D-8EE752B08B09Q33958570-3C459A99-1DE3-4FB4-B102-027405457B4CQ34177643-B1EBAF7B-845E-44D8-B489-7CAE5256DB20Q34182013-8A82DA3B-E59E-4D05-A533-ECD08B69EFF4Q34240955-AC3A716F-70B5-4285-B180-DCC939635E17Q34240985-C55E4B16-215F-4AFE-91BA-964B52B562D4Q34822538-C7EE0F01-2D64-4920-BB11-ED177EBEF501Q35236370-16AA9827-FBA8-48D7-8DBB-FC4E57086D18Q36258557-60D2E1CA-42DE-4105-AF4B-34A3426CE62BQ36258561-5E1A67F5-4E15-43DC-8722-C1D1E2BDE7CDQ36443014-4D0C1A55-D375-4DFE-B2DA-3746BD3428EAQ36473542-99C6FE40-F9F8-474A-9CD1-DAA7AC674AFCQ36613868-69327A91-C372-4A10-B7DB-B10FC4292A65Q37307611-DB8C4F25-0F28-4AF9-946A-A57EBF388770Q37610236-6CF0239B-0282-4847-AF65-27FBC36BF316Q38095762-B38E3683-A718-4877-825C-69033E4D9201Q38154183-F8C7F1BC-CD28-4B9A-9EFD-479585F7F350Q38193069-573EF194-D435-43E3-AD67-138D249D315EQ38217992-17077229-C0F4-411A-951F-1B2FC18E84B2Q38268023-8AC01BBC-8C5A-430C-9EDB-19B03D41FDE2Q38345718-5F1AE2B4-27E1-4880-82BF-C2AEFECDDD1DQ38448948-BA0B9F06-3274-4070-A233-8C3D71A16852Q38528316-1731CDE7-2834-435B-B6DD-110E54A02411Q38605488-F7FBEC3F-59A2-4D3D-BBD3-0683A205AA5AQ38739577-340D116B-C71E-4829-BB28-4A66DEE67F84Q40385595-B3CE17D4-0542-4478-9556-58C225064149Q44048479-5903CD0A-251F-486F-A516-809D891855EBQ44247108-6D5EDD95-33D5-42DD-8CA8-102DE454A404Q46830215-17812B0C-B3DF-4D60-8831-90BC4A9BBCBE
P2860
Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: an open-label pilot study.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh-hant
name
Olanzapine treatment of childr ...... rs: an open-label pilot study.
@en
Olanzapine treatment of childr ...... rs: an open-label pilot study.
@nl
type
label
Olanzapine treatment of childr ...... rs: an open-label pilot study.
@en
Olanzapine treatment of childr ...... rs: an open-label pilot study.
@nl
prefLabel
Olanzapine treatment of childr ...... rs: an open-label pilot study.
@en
Olanzapine treatment of childr ...... rs: an open-label pilot study.
@nl
P2093
P1476
Olanzapine treatment of childr ...... rs: an open-label pilot study.
@en
P2093
C J McDougle
J P Holmes
M N Potenza
P356
10.1097/00004714-199902000-00008
P407
P577
1999-02-01T00:00:00Z